FunPep Company Limited (4881.T)
JPY 131.0
(0.77%)
JPY 131.0
(0.77%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 189.32 Million JPY | -36.49% |
| 2022 | 298.1 Million JPY | 58.0% |
| 2021 | 188.67 Million JPY | 24.05% |
| 2020 | 152.09 Million JPY | 76.93% |
| 2019 | 85.96 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 229.95 Million JPY | 21.46% |
| 2024 Q2 | 541.15 Million JPY | 135.34% |
| 2023 Q2 | 226.21 Million JPY | -26.88% |
| 2023 FY | 189.32 Million JPY | -36.49% |
| 2023 Q3 | 201.09 Million JPY | -11.1% |
| 2023 Q4 | 189.32 Million JPY | -5.85% |
| 2023 Q1 | 309.38 Million JPY | 3.78% |
| 2022 Q3 | 206.4 Million JPY | 0.0% |
| 2022 FY | 298.1 Million JPY | 58.0% |
| 2022 Q4 | 298.1 Million JPY | 44.43% |
| 2021 FY | 188.67 Million JPY | 24.05% |
| 2020 FY | 152.09 Million JPY | 76.93% |
| 2019 FY | - JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 94.169% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -198.566% |
| GNI Group Ltd. | 26.34 Billion JPY | 99.281% |
| Linical Co., Ltd. | 10.3 Billion JPY | 98.163% |
| Trans Genic Inc. | 3.81 Billion JPY | 95.034% |
| MEDINET Co., Ltd. | 590.2 Million JPY | 67.922% |
| Soiken Holdings Inc. | 697.02 Million JPY | 72.838% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 93.733% |
| AnGes, Inc. | 2.78 Billion JPY | 93.213% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | 63.138% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 99.791% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | 46.408% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | 88.525% |
| Carna Biosciences, Inc. | 472.35 Million JPY | 59.919% |
| CanBas Co., Ltd. | 91.98 Million JPY | -105.814% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 82.688% |
| RaQualia Pharma Inc. | 809.83 Million JPY | 76.622% |
| Chiome Bioscience Inc. | 593.73 Million JPY | 68.113% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 95.55% |
| PeptiDream Inc. | 29.11 Billion JPY | 99.35% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | 66.58% |
| Ribomic Inc. | 155.8 Million JPY | -21.51% |
| SanBio Company Limited | 2.25 Billion JPY | 91.604% |
| Healios K.K. | 11.28 Billion JPY | 98.322% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | 24.653% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | 48.693% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | 21.604% |
| StemRIM | 187 Million JPY | -1.243% |
| CellSource Co., Ltd. | 677.73 Million JPY | 72.065% |
| Kringle Pharma, Inc. | 596.95 Million JPY | 68.285% |
| Stella Pharma Corporation | 1.44 Billion JPY | 86.885% |
| TMS Co., Ltd. | 97.68 Million JPY | -93.803% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -106.925% |
| Cuorips Inc. | 200.96 Million JPY | 5.791% |
| K Pharma,Inc. | 209.13 Million JPY | 9.472% |
| Takara Bio Inc. | 11.42 Billion JPY | 98.342% |
| ReproCELL Incorporated | 741.03 Million JPY | 74.451% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | 79.37% |
| StemCell Institute Inc. | 3.85 Billion JPY | 95.083% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | 79.159% |
| CellSeed Inc. | 301.04 Million JPY | 37.111% |